MX2023013018A - Anticuerpos anti-5t4 y usos de estos. - Google Patents

Anticuerpos anti-5t4 y usos de estos.

Info

Publication number
MX2023013018A
MX2023013018A MX2023013018A MX2023013018A MX2023013018A MX 2023013018 A MX2023013018 A MX 2023013018A MX 2023013018 A MX2023013018 A MX 2023013018A MX 2023013018 A MX2023013018 A MX 2023013018A MX 2023013018 A MX2023013018 A MX 2023013018A
Authority
MX
Mexico
Prior art keywords
antibodies
disclosed
cdrs
cancer
present disclosure
Prior art date
Application number
MX2023013018A
Other languages
English (en)
Spanish (es)
Inventor
Liat Dassa
Oren Bogin
Original Assignee
Immunorizon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunorizon Ltd filed Critical Immunorizon Ltd
Publication of MX2023013018A publication Critical patent/MX2023013018A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2023013018A 2021-05-04 2022-05-02 Anticuerpos anti-5t4 y usos de estos. MX2023013018A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163183636P 2021-05-04 2021-05-04
PCT/IL2022/050451 WO2022234570A1 (en) 2021-05-04 2022-05-02 Anti-5t4 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2023013018A true MX2023013018A (es) 2024-01-18

Family

ID=83932628

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013018A MX2023013018A (es) 2021-05-04 2022-05-02 Anticuerpos anti-5t4 y usos de estos.

Country Status (11)

Country Link
US (1) US20240228658A1 (https=)
EP (1) EP4334362A4 (https=)
JP (1) JP2024517760A (https=)
KR (1) KR20240004837A (https=)
CN (1) CN117279951A (https=)
AU (1) AU2022270453A1 (https=)
BR (1) BR112023023086A2 (https=)
CA (1) CA3217716A1 (https=)
IL (1) IL308203A (https=)
MX (1) MX2023013018A (https=)
WO (1) WO2022234570A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024183811A1 (en) * 2023-03-08 2024-09-12 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-5t4 antibodies and uses thereof
CN121002067A (zh) * 2023-04-03 2025-11-21 非同（成都）生物科技有限公司 抗5t4抗体及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012009709A1 (en) * 2010-07-16 2012-01-19 Sudhir Paul Hiv cd4 binding site based covalent immunogen compositions
WO2015051159A1 (en) * 2013-10-02 2015-04-09 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
MX384198B (es) * 2014-12-19 2025-03-14 Chiome Bioscience Inc Proteina de fusion que comprende tres dominios de union a 5t4 y cd3.
SG11202008399QA (en) * 2018-03-12 2020-09-29 Genmab As Antibodies
CN116096754A (zh) * 2020-05-04 2023-05-09 免疫里森公司 前体三特异性抗体构建体及其使用方法

Also Published As

Publication number Publication date
US20240228658A1 (en) 2024-07-11
WO2022234570A1 (en) 2022-11-10
AU2022270453A1 (en) 2023-12-21
BR112023023086A2 (pt) 2024-01-30
EP4334362A4 (en) 2025-04-16
KR20240004837A (ko) 2024-01-11
CA3217716A1 (en) 2022-11-10
EP4334362A1 (en) 2024-03-13
CN117279951A (zh) 2023-12-22
IL308203A (en) 2024-01-01
JP2024517760A (ja) 2024-04-23

Similar Documents

Publication Publication Date Title
AR119295A1 (es) Moléculas de unión a antígeno ligantes de cea
MX2022013163A (es) Anticuerpo contra nectin-4 y aplicacion del mismo.
ZA202100721B (en) Anti-mesothelin antibodies
PH12018501220A1 (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
MX2024002238A (es) Anticuerpos anti-ccr8 y uso de los mismos.
WO2021227307A8 (zh) 抗cd73抗体及其用途
ECSP19010852A (es) Anticuerpos anti-pd-1, un método de producción y un método para su uso
MY179866A (en) Bi-specific monovalent diabodies that are capable of binding to gpa33 and cd3, and uses thereof
RU2014138039A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
WO2019234241A8 (en) ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT
NZ611269A (en) Neutralizing anti-ccl20 antibodies
NZ594682A (en) Fully human antibodies specific to cadm1
ZA202206993B (en) Anti-lilrb1 antibody and uses thereof
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.
ZA202008095B (en) Humanized antibodies against psma
MX2023013018A (es) Anticuerpos anti-5t4 y usos de estos.
MX2023014069A (es) Composiciones y métodos para el tratamiento del cáncer de próstata.
ZA202302392B (en) Antibodies against ilt2 and use thereof
MX2025003476A (es) Anticuerpos anti-il-27 y usos de los mismos
ZA202213434B (en) Anti-lilrb1 antibody and uses thereof
MX2022015966A (es) Anticuerpos y metodos para tratar enfermedades asociadas a claudina.
PH12022552725A1 (en) Anti-ox40 antibody and uses thereof
WO2019183093A8 (en) High affinity neutralizing monoclonal antibodies to programmed death ligand 1 (pd-l1) and uses thereof
MX2025004473A (es) Novedosos anticuerpos anti-napi2b y conjugados-anticuerpo-droga basados en ellos, metodos terapeuticos y usos de los mismos
MX2023006777A (es) Composiciones y métodos que comprenden antagonistas de proteína 2 relacionada con frizzled secretada (sfrp2).